A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Inclusion Criteria:

* Men or women 18 years or older with histologically or cytologically confirmed advanced non-squamous NSCLC (unresectable stage IIIB with pericardial or pleural effusion or stage IV/recurrent)
* Measureable disease per RECIST criteria modified
* ECOG performance status of 0 or 1
* Ability to take oral medications
* Competent to give written informed consent

Exclusion Criteria:

* Current or prior history of CNS metastases
* Any prior chemotherapy for advanced NSCLC
* History of pulmonary hemorrhage or gross hemoptysis within 6 months prior to randomization
* Prior targeted therapies
* Known history of allergy or hypersensitivity to paclitaxel or carboplatin
* History of arterial or venous thrombosis within 52 weeks prior to randomization
* History of bleeding diathesis or non-pulmonary bleeding within 14 days prior to randomization
* Peripheral neuropathy \> grade 1 per CTCAE Version 3.0
* Myocardial infarction, cerebrovascular accident, grade 2 or greater peripheral vascular disease, transient ischemic attack, congestive heart failure, percutaneous transluminal coronary angioplasty/stent, ongoing arrythmias requiring medication or unstable angina within 52 weeks prior to randomization
* Any kind of disorder that compromises the ability of the subject to comply with the study procedures
* Uncontrolled hypertension as defined by resting blood pressure \> 150/90 mm Hg. Anti-hypertensive medications are allowed if hypertension is stably controlled at the time of randomization.
* Participation in therapeutic clinical trials or currently receiving other investigational treatment(s) within 30 days prior to randomization
* Pregnant or breast feeding women
* Known to be HIV, hepatitis B surface antigen, or hepatitis C positive